Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey | PLOS ONE
![Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO)](https://i1.rgstatic.net/ii/profile.image/1069256951209984-1631942131234_Q512/Gaetano-Pezzicoli-2.jpg)
Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO)
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
![Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4 Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4](https://i1.rgstatic.net/ii/profile.image/394509356683264-1471069768460_Q512/Nicola-Silvestris.jpg)
Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4
![Francesco ATZORI | Attending Phisician | Doctor of Medicine | Università degli studi di Cagliari, Cagliari | UNICA | Azienda Ospedaliero-Universitaria di Cagliari Francesco ATZORI | Attending Phisician | Doctor of Medicine | Università degli studi di Cagliari, Cagliari | UNICA | Azienda Ospedaliero-Universitaria di Cagliari](https://i1.rgstatic.net/ii/profile.image/1096678220267524-1638479871914_Q512/Francesco-Atzori.jpg)
Francesco ATZORI | Attending Phisician | Doctor of Medicine | Università degli studi di Cagliari, Cagliari | UNICA | Azienda Ospedaliero-Universitaria di Cagliari
![Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8 Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8](https://i1.rgstatic.net/ii/profile.image/272303485353996-1441933618320_Q512/Sebastiano-Buti.jpg)
Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8
Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey | PLOS ONE
![Alessandro RIZZO | Medical Doctor | Ospedale Oncologico "Giovanni Paolo II" di Bari, Bari | IRCCS Bari | Department of Medical Oncology Alessandro RIZZO | Medical Doctor | Ospedale Oncologico "Giovanni Paolo II" di Bari, Bari | IRCCS Bari | Department of Medical Oncology](https://i1.rgstatic.net/ii/profile.image/977348979589124-1610029563829_Q512/Alessandro-Rizzo-4.jpg)
Alessandro RIZZO | Medical Doctor | Ospedale Oncologico "Giovanni Paolo II" di Bari, Bari | IRCCS Bari | Department of Medical Oncology
![Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.14.48/asset/images/medium/figure3.gif)
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
![Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921003919-ga1.jpg)